Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Hidradenitis Suppurativa
NCT03960268Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- May 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brodalumab in hidradenitis suppurativa (HS), sponsored by The Rockefeller University. Primary endpoints: Biomarkers of disease activity and clinical response at 24 weeks and Incidence of Treatment-Emergent Adverse Events at 24 weeks. Started May 2019; status: completed.
02
Drugs
brodalumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03960268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960268.